Want to stay on top of the science and politics driving biotech today?
Sign up
to get our biotech newsletter in your inbox.
Morning! The impact of President Trump’s “most-favored nation” drug-pricing push can be hard to decipher, but the policy is starting to look less like a slogan and more like a real pressure point that could mean higher prices abroad.
Meanwhile, 93-year-old vaccine legend Stanley Plotkin is watching vaccination rates slip and calling the anti-vaccine turn inside government what he thinks it is: “stupid” and “immoral.” Also, a pointed warning about at-home ketamine oversight and Novartis reaches a quiet settlement in the Henrietta Lacks case.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/02/biotech-news-merck-renal-cell-carcinoma-drug/)
